There’s something newly HIV positive people can do to join the fight against HIV, even before beginning traditional standard-of-care treatment. They can join a clinical study assessing the safety and effectiveness of a new class of HIV treatment called allosteric HIV-1 inhibitor (ALLINI).
With your help, we hope to continue making advancements that improve treatment options for the future of people living with HIV (PLHIV).
There’s something newly HIV positive people can do to join the fight against HIV, even before beginning traditional standard-of-care treatment. They can join a clinical study assessing the safety and effectiveness of a new class of HIV treatment called allosteric HIV-1 inhibitor (ALLINI).
With your help, we hope to continue making advancements that improve treatment options for the future of people living with HIV (PLHIV).
There’s something newly HIV positive people can do to join the fight against HIV, even before beginning traditional standard-of-care treatment. They can join a clinical study assessing the safety and effectiveness of a new class of HIV treatment called allosteric HIV-1 inhibitor (ALLINI).
With your help, we hope to continue making advancements that improve treatment options for the future of people living with HIV (PLHIV).
If you are newly diagnosed with HIV-1 or if you are a healthcare provider in position to recommend this study, participants may receive:
The ST PHARM SToPHIV-1 Study
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that weakens the immune system. Worldwide, as of 2017, about 37 million people had HIV1, with roughly 40% not on any treatment2.
Per the CDC, in 2021, some 36,136 people ages 13+ received an HIV diagnosis in the U.S. and dependent areas. In terms of race, 40% were Black/African American; 29% were Hispanic/Latino, and 25% were White—which is why diversity in clinical trials is key to ensuring that new drugs will work for everyone3.
In total, 1.2 million people in the U.S. were believed to have HIV by the end of 2021. Of those, 87% knew they had it—which means that 13% remained undiagnosed3.
1. Justiz Vaillant AA, Naik R. HIV-1 associated opportunistic infections. [Updated 2022 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539787/
2. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6(12):e831-59.
* NOTE: Those who have taken PrEP and/or PEP therapy may still qualify to enroll if they meet specific conditions. This can be discussed with the Principal Investigator.
Download the Welcome Guide for more details about this study and your responsibilities.
All study-related care and study-related medication will be provided at no cost to the participant.
Kaiser Permenente
Los Angeles Medical Center
Los Angeles, California 90027
Ruane Clinical Research, Inc.
Los Angeles, California 90036
Kaiser Permenente
Los Angeles Medical Center
Los Angeles, California 90027
Ruane Clinical Research, Inc.
Los Angeles, California 90036
USF Health South Tampa Center For Advanced Healthcare
Tampa, FL 33602-3511
Be Well Medical Center
Berkley, Michigan 48072
Saint Michael’s Medical Center
Newark, New Jersey 07102
South Jersey Infectious Disease
Somers Point, New Jersey 08244
North Shore University Hospital
Manhasset, NY 11030
Atrium Health Wake Forest Baptist Medical Center – PPDS
Winston-Salem, North Carolina 27157
St Hope Foundation, Inc
Bellaire, Texas 77401
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas 75246
Find useful information about STP0404
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
©2021 Acurian, Inc. All rights reserved.
*In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.
